Keywords: cochrane, review, finds, gsk, avandia, better, hba1c
Cochrane Review finds GSK's Avandia is no better at HbA1c control than cheaper drugs
Article | 23 July 2007
A Cochrane Systematic Review of data from 18 trials involving a total of 8,432 people found no evidence that GlaxoSmithKline's Avandia (rosiglitazone) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
